Structure Therapeutics

Clinical-stage biotech. Lead asset aleniglipron: oral small-molecule GLP-1 agonist. Two positive Phase 2 readouts; high-dose 11%+ placebo-adjusted weight loss at 36 weeks. Roche licensing deal ($100M) for additional assets.